Posts Tagged ‘type 2 diabetes’

Loose Takes on a Study of Red Meat and Type 2 Diabetes

October 25, 2023 — It’s a popular cause. Red meat production is a problem for the climate. Add that to ethical concerns some people have about consuming meat, and the push to reduce red meat consumption makes total sense. But when people start spinning misleading narratives about observational research and using them to promote this otherwise worthy idea, they’re […]

Did Tirzepatide Steal the Show at EASD?

October 6, 2023 — At EASD this week, it was quite a showing for tirzepatide. Sold under the brand name Mounjaro, it’s already available for treating diabetes and it’s awaiting approval for treating obesity. Based on the research presented at EASD this week, semaglutide might be looking a little like old news. For tirzepatide, a total of 11 presentations […]

A Fierce Debate at EASD 2023 About Diabetes Remission

October 5, 2023 — Two professors yesterday at the EASD meeting engaged in a fierce and collegial debate about the feasibility of lasting remission in type 2 diabetes with very low calorie diets. Professor Kamlesh Khunti brought a polished presentation of objective data. He was unequivocal. Is lasting remission feasible in a real world setting? “It’s a definite no […]

The Effect of Hookworms on Metabolic Health

August 29, 2023 — Bet you never saw this one coming. We did not. But a new RCT published in Nature Communications suggests that hookworms might have benefits for the metabolic health of people with insulin resistance that puts them at risk for type 2 diabetes. This was a phase 1 study with the primary aim of confirming the […]

ADA2023: An Amazing 3-in-1 Obesity Medicine

June 27, 2023 — The last of four big days at ADA2023 brought us astonishing results from three studies of a new obesity medicine, retatrutide. This is the first 3-in-1 metabolic receptor agonist to advance this far in clinical trials as a medicine for obesity or diabetes. Researchers presented phase 2 results for obesity, diabetes, and NAFLD – three […]

ADA2023: A Golden Age of Obesity Medicine?

June 26, 2023 — “We may be on the cusp of an era of astonishing innovation – the limits of which aren’t even clear yet,” writes David Wallace-Wells in the New York Times. Among other breakthroughs, he cites the transformation in care that semaglutide and tirzepatide are bringing for the most prevalent chronic disease in the world – obesity. […]

Headline Fantasies: Coffee and Obesity

March 17, 2023 — “Coffee could slash obesity,” says the New York Post. Now you might think that cynical folks at the Post just make this stuff up because it’s so obviously false. But in fact, they have help from PR by the BMJ, and they’re not alone. The BMJ managed to induce quite a few news outlets last […]

How Helpful Is Vitamin D in Prediabetes?

February 9, 2023 — Vitamin D is an illusory panacea. Popular fascination with this “sunshine vitamin” has drawn people to latch onto associations that it has with many conditions. But those associations, when tested, often turn out to be confounded. So does a new systematic review and meta-analysis of vitamin D in prediabetes tell a different story? Anastassios Pittas […]

Big Claims, Vexing Flaws of an Intermittent Fasting Study

December 21, 2022 — Clinical research is hard to do right – especially if the goal is to discover the true answer to a scientific question. Because scientists are human, they bring passion to their work. But they have to set aside those passions in designing and conducting research so that their research will hold up to scrutiny. Along […]

New Obesity Surgery Guidelines: 5 Things New

October 24, 2022 — On Friday, ASMBS and IFSO announced new clinical guidelines for obesity surgery – the first update to guidelines in more than 30 years. Way back in 1991, NIH published a consensus statement that established bariatric surgery as a safe and effective option for treating severe obesity. Needless to say, we’ve learned a lot about metabolic […]